Suppr超能文献

白细胞介素-8 作为 2019 年冠状病毒病患者疾病预后的生物标志物。

Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients.

机构信息

Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Cheng Lab, Suzhou Institute of Systems Medicine, Suzhou, China.

出版信息

Front Immunol. 2021 Jan 8;11:602395. doi: 10.3389/fimmu.2020.602395. eCollection 2020.

Abstract

The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.

摘要

由严重呼吸综合征冠状病毒 2(SARS-CoV-2)感染引起的 2019 年冠状病毒病(COVID-19)广泛流行,导致了严重的全球公共卫生紧急情况。然而,目前尚无敏感的生物标志物可预测 COVID-19 患者的疾病预后。在这里,我们已将白细胞介素-8(IL-8)鉴定为预测 COVID-19 患者不同疾病严重程度和预后的候选生物标志物。虽然严重 COVID-19 患者的血清 IL-6 明显升高,但轻度综合征的 COVID-19 患者中很容易检测到血清 IL-8。此外,IL-8 水平与同一 COVID-19 患者不同阶段的总体临床疾病评分的相关性优于 IL-6 水平。因此,我们的研究表明,IL-6 和 IL-8 可分别用于严重 COVID-19 患者和 COVID-19 疾病预后的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f14e/7820901/61bc71bebf71/fimmu-11-602395-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验